Results 241 to 250 of about 414,407 (362)
OP25. NEW GLUCOCORTICOIDS: SELECTIVE GLUCOCORTICOID RECEPTOR AGONISTS, NO-GLUCOCORTICOIDS AND LONG-CIRCULATING LIPOSOMAL GLUCOCORTICOIDS [PDF]
openaire +1 more source
Objective The therapeutic effects of telitacicept combined with standard of care (SoC) in childhood‐onset systemic lupus erythematosus (cSLE) remain unclear. This study aims to evaluate its efficacy in comparison with belimumab combined with SoC.
Chong Luo +15 more
wiley +1 more source
Cushing Syndrome, Hypercortisolism, and Glucose Homeostasis: A Review. [PDF]
DeFronzo RA, Auchus RJ.
europepmc +1 more source
CHRDL2 activates the PI3K/AKT pathway to ameliorate glucocorticoid-induced damages to bone microvascular endothelial cells (BMECs) [PDF]
Xianzhe Huang +3 more
openalex +1 more source
Objective Systemic lupus erythematosus (SLE) is characterized by increased type I interferon (IFN‐I) and autoantibody production. This study aimed to identify drugs that can inhibit both IFN‐I and autoantibody production. Methods We identified an inhibitor of IFN‐I production from a chemical library.
Takehiro Hirayama +16 more
wiley +1 more source
Efficacy and Safety of Pirfenidone for Mitigation of Interstitial Lung Abnormalities in COVID-19 Patients: A Meta-Analysis. [PDF]
Zhang Z +5 more
europepmc +1 more source
Background Pain is the hallmark symptom of osteoarthritis (OA) and its biological drivers remain poorly understood. While the role of innate immunity in OA has been extensively studied, the involvement of adaptive immunity, in particular regulatory T cells (Tregs), is not well understood. Methods We performed omics profiling of peripheral blood from 46
Marie Binvignat +26 more
wiley +1 more source
The Bidirectional Interaction Between NF-<i>κ</i>B and Glucocorticoid Receptor: Underlying Mechanisms of Chronic Stress-Induced Pathology. [PDF]
Yu HJ, Park HJ, Lee B, Hahm DH.
europepmc +1 more source
Objective This study aims to investigate the impact of nonsteroidal anti‐inflammatory drug (NSAID) intake on radiographic spinal progression in axial spondyloarthritis (axSpA), considering different NSAID types (COX‐2 inhibitors [COX2i] and nonselective NSAIDs [ns‐NSAIDs]) and disease subgroups (radiographic [r‐axSpA] and nonradiographic [nr‐axSpA ...
Murat Torgutalp +8 more
wiley +1 more source

